A clinical trial involving desmopressin was registered on October 2, 2026. The study, titled "FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps," is listed under identifier NCT07855315.
The trial is categorized as phase not applicable and its current status is not yet recruiting. According to the registration, the study will examine the use of intranasal desmopressin in combination with or without functional endoscopic sinus surgery, commonly known as FESS, in patients with chronic rhinosinusitis accompanied by nasal polyps.
No participants have been enrolled yet, and no outcomes or results have been reported at this stage. As the status indicates, recruitment has not begun, so no efficacy or safety data from this specific trial are currently available.
Further details, including eligibility criteria and expected timelines, may be updated on the official registry as the trial progresses toward recruitment. Readers interested in this development can monitor the registry entry for status changes.
For additional background on desmopressin, including its approved uses and general profile, readers can consult the compound overview.